

Filed On Behalf Of:

Novartis AG and LTS Lohmann Therapie-Systeme AG

By:

Raymond R. Mandra
ExelonPatchIPR@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner

v.

NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
Patent Owners

Inter Partes Review No. 2015-00265

U.S. Patent 6,316,023

PATENT OWNERS' MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8(a)(2)

REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(2), the undersigned states that Novartis AG (“Novartis”) and LTS Lohmann Therapie-Systeme AG (formerly LTS Lohmann Therapie-Systeme GmbH Co. KG) (“LTS”) are the Patent Owners and real parties-in-interest in IPR2015-00265 directed to U.S. Patent No. 6,316,023 (“the ’023 Patent”).

RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)

The ’023 Patent is being asserted in the following patent infringement lawsuits: (1) Novartis Pharm. Corp. et al. v. Par Pharm. Inc. et al., 1:11-cv-01077 (D. Del.); (2) Novartis Pharm. Corp. et al. v. Watson Labs. Inc. et al., 1:11-cv-01112 (D. Del.); (3) Novartis Pharm. Corp. et al. v. Actavis, Inc. et al., 1:13-cv-00371 (D. Del.); (4) Novartis Pharm. Corp. et al. v. Noven Pharm. Inc. et al., 1:13-cv-00527 (D. Del.); (5) Novartis Pharm. Corp. et al. v. Noven Pharm. Inc., 1:14-cv-00111 (D. Del.); (6) Novartis Pharm. Corp. et al. v. Mylan Inc. et al., 1:14-cv-00777 (D. Del.); (7) Novartis Pharm. Corp. et al. v. Mylan Inc. et al., 1:14-cv-00106 (N.D.W.V.); (8) Novartis Pharm. Corp. et al. v. Zydus Noveltech Inc. et al., 1:14-cv-01104 (D. Del.); (9) Novartis Pharm. Corp. et al. v. Zydus Noveltech Inc. et al., 1:14-cv-05405 (D.N.J.); (10) Watson Labs. Inc. et al. v. Novartis Pharm. Corp. et al., 14-1799 (C.A.F.C.); (11) Novartis Pharm. Corp. et al. v. Par Pharm.

Inc. et al., 15-1061 (C.A.F.C.); and (12) Par Pharm. Inc. v. Novartis Pharm. Corp. et al., 15-1120 (C.A.F.C.).

The '023 Patent is being asserted in the following *Inter Partes* Review proceeding, Novartis Pharm. Corp. et al. v. Noven Pharm. Inc., IPR2014-00549 (P.T.A.B.).

**IDENTIFICATION OF LEAD AND BACK-UP COUNSEL
PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10**

Pursuant to 37 C.F.R. §§ 42.8(b)(3) and 42.10, Novartis and LTS designate Raymond R. Mandra (Reg. No. 34,382) as lead counsel and Nicholas N. Kallas (Reg. No. 32,530) as back-up counsel.

A power of attorney from each Patent Owner is being submitted with this Notice.

SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)

Novartis and LTS may be served electronically using the following e-mail address:

ExelonPatchIPR@fchs.com

Novartis and LTS may be served by postal mailing, hand-delivery, telephone or facsimile as follows:

Raymond R. Mandra
Fitzpatrick, Cella, Harper & Scinto
1290 Avenue of the Americas
New York, NY 10104

Telephone: (212) 218-2100
Facsimile: (212) 218-2200

Respectfully submitted,

Dated: December 4, 2014

/Raymond R. Mandra/
Raymond R. Mandra
Registration No. 34,382
Lead Counsel for Patent Owners
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100

CERTIFICATE OF SERVICE

I certify that a copy of the Patent Owners' Mandatory Notices Under 37 C.F.R. § 42.8(a)(2) was served on December 4, 2014 by causing it to be sent by email to counsel for Petitioner at the following email addresses:

BoxMylan2@knobbe.com

Dated: December 4, 2014

/Raymond R. Mandra/
Raymond R. Mandra
Registration No. 34,382
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100